MDNA19-MDNA213 / Medicenna - LARVOL DELTA

Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting (GlobeNewswire) - "MDNA19-MDNA213: In vitro data demonstrate that the BiSKIT retains strong binding affinity and selectivity to both the IL-13Rα2 and CD122 (IL-2Rβ) receptors and stimulates cancer killing effector T cells and NK cells without stimulating cells associated with toxicity or pro-tumor immune suppression. This BiSKIT enables localization and retention of our IL-2 Superkines in the TME."

Preclinical • Oncology